Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and α1-antichymotrypsin type A allele in Alzheimer's disease

Makoto Higuchi, Hiroyuki Arai, Takuma Nakagawa, Susumu Higuchi, Taro Muramatsu, Sachio Matsushita, Yo Ichi Kosaka, Masatoshi Itoh, Hidetada Sasaki

Research output: Contribution to journalArticle

22 Citations (Scopus)


TWENTY Alzheimer's disease (AD) patients with defined apolipoprotein E (APOE), α1-antichymotrypsin (ACT) and presenilin-1 (PS-1) intronic genotypes were examined to quantify the regional cerebral metabolic rate of glucose (rCMRglc) using positron emission tomography (PET) and 18F-2- fluoro-2-deoxy-D-glucose (FDG). The frontal rCMRglc was significantly increased in patients with the APOE ε4 allele in a dose-dependent fashion. In contrast, the temporo-parietal rCMRglc was significantly reduced in ACT type A allele (ACT*A) carriers compared with those in non-ACT*A carriers. The PS-1 type 1 intronic allele had no significant effects on rCMRglc in any cerebral region. These results suggest that both the APOE and ACT genes may play a distinct role in the progression of AD as monitored by imaging studies of cerebral glucose utilization.

Original languageEnglish
Pages (from-to)2639-2643
Number of pages5
Issue number12
Publication statusPublished - 1997 Jan 1



  • Alzheimer's disease
  • Apolipoprotein E
  • Glucose metabolism
  • Positron emission tomography
  • Presenilin-1
  • α-antichymotrypsin

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this